China Resources Double-Crane Pharmaceutical (600062.SH) intends to be selected in the national centralized procurement of Pharmaceuticals.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that on December 12, 2024, the company and some of its subsidiaries...

Zhitong FinanceDec 13 05:38 ET

Here's Why China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt Responsibly

Simply Wall StDec 12 21:49 ET

China Resources Double-Crane Subsidiaries Secure Drug Approvals

MT NewswiresNov 28 22:41 ET

China Resources Double-Crane Pharmaceutical (600062.SH): Some products of its subsidiary have obtained pharmaceutical registration certificates.

On November 28, great wisdom announced that its wholly-owned subsidiary china resources double-crane pharmaceutical (600062.SH), its wholly-owned subsidiary Li Min Pharmaceutical Industry (Jinan) Co., Ltd. received the National Medical Products Administration (hereinafter referred to as “NMPA”) issued the registration certificate for Sacubitril Valsartan Tablets, and its wholly-owned subsidiary Anhui Shuanghe Pharmaceuticals Co., Ltd. received the NMPA issued the registration certificate for Sodium Bicarbonate Ringer Injection. Sacubitril Valsartan Tablets are used in adult patients with chronic heart failure with reduced ejection fraction (NYHA II-IV, LVEF ≤ 40%) to reduce cardiovascular death and heart failure.

Gelonghui FinanceNov 28 03:53 ET

Double-Crane Pharmaceutical Gets Approval for China Clinical Trial of Weight Loss Drug

MT NewswiresNov 24 22:42 ET

Those Who Invested in China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Three Years Ago Are up 104%

Simply Wall StNov 20 17:57 ET